Login / Signup

Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator.

Alexandros ProtonotariosRiccardo BarianiChiara CappellettoMenelaos PavlouAlba García-GarcíaAlberto CiprianiIoannis ProtonotariosAdrian RivasRegitze WittenbergMaddalena GraziosiZafeirenia XylouriJosé M Larrañaga-MoreiraAntonio De LucaRudy CeleghinKalliopi PilichouAthanasios BakalakosLuis Rocha LopesKonstantinos SavvatisDavide StolfoMatteo Dal FerroMarco MerloCristina BassoJavier Limeres FreireJosé F Rodriguez PalomaresToru KuboTomas Ripoll-VeraRoberto Barriales VillaLoizos AntoniadesJens MogensenPablo García-PavíaKarim WahbiElena BiaginiAris AnastasakisAdalena TsatsopoulouEsther Zorio-GrimaJuan Ramon Gimeno-BlanesJose Manuel Garcia-PinillaPetros SyrrisGianfranco SinagraBarbara BaucePerry Mark Elliott
Published in: European heart journal (2022)
The 2019 ARVC risk model performs reasonably well in gene-positive ARVC (particularly for PKP2) but is more limited in gene-elusive patients. Genotype should be included in future risk models for ARVC.
Keyphrases
  • end stage renal disease
  • genome wide
  • chronic kidney disease
  • heart failure
  • ejection fraction
  • newly diagnosed
  • copy number
  • transcription factor